ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

22,365Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 491

$2.87M Total Retail Price of All Prescriptions

Rank: 2 out of 491

1,861 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
91% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

5% of this provider’s 16,047 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

36% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$129 was the average price of a prescription from this provider, compared to $218 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
NAMENDA 3,474 2,999 10 1 4
LEVETIRACETAM 1,295 580 10 2 5
PRIMIDONE 1,076 910 10 3 11
CARBIDOPA-LEVODOPA 1,034 985 4 2
ZONISAMIDE 920 465 10 5 22
DONEPEZIL HCL 854 755 6 3
EXELON 843 793 7 12
ROPINIROLE HCL 697 613 10 8 9
AMITRIPTYLINE HCL 675 366 R 9 14
LAMOTRIGINE 605 258 10 8
TOPIRAMATE 602 202 10 11 7
AZILECT 574 542 10 12 16
OXCARBAZEPINE 504 277 10 13 26
MECLIZINE HCL 442 360 14 60
PRAMIPEXOLE DIHYDROCHLORIDE 425 414 10 15 15
CYCLOBENZAPRINE HCL 387 253 R 16 43
CLOPIDOGREL 383 287 17 33
GABAPENTIN 355 227 18 1
ZIPRASIDONE HCL 326 311 19 88
PHENYTOIN SODIUM EXTENDED 314 164 20 17
NORTRIPTYLINE HCL 298 221 21 32
ESCITALOPRAM OXALATE 283 204 22 42
PROPRANOLOL HCL 278 195 23 30
PLAVIX 258 188 24 41
TIZANIDINE HCL 258 140 24 20
CARBAMAZEPINE 217 106 26 25
DIVALPROEX SODIUM ER 214 85 27 29
DIVALPROEX SODIUM 206 89 28 40
VIMPAT 196 23 29 19
GEODON 162 158 30 119
LYRICA 148 70 31 10
DICLOFENAC SODIUM 147 102 32 87
RIVASTIGMINE 131 116 33 68
CYMBALTA 130 68 34 13
RISPERIDONE 119 96 35 57
LEXAPRO 110 83 36 110
BACLOFEN 99 41 37 21
DIPYRIDAMOLE 99 82 R 37 141
LUNESTA 96 57 39 117
QUETIAPINE FUMARATE 93 89 40 34
GALANTAMINE HBR 90 80 41 36
AMANTADINE 86 80 42 35
MELOXICAM 81 40 43 37
ZOLPIDEM TARTRATE 76 45 44 28
COMTAN 69 64 45 59
AGGRENOX 68 62 46 44
PYRIDOSTIGMINE BROMIDE 67 56 47 48
STALEVO 150 66 62 48 99
VOLTAREN 62 55 49 127
MIDODRINE HCL 55 42 50 164
NEXIUM 54 48 51 129
CITALOPRAM HBR 53 40 52 18
STALEVO 200 53 53 10 52 129
LEVOTHYROXINE SODIUM 51 51 54 70
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 13, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.